ICON plc, a clinical research organization, expanded its portfolio of artificial intelligence (AI) tools that aim to deliver efficiencies across the clinical trial process, including study startup, ...
The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in ...